Table 1: Relationship between clinicopathological factors and miR-21 expression in patients with GC.

ParametersmiR-21 expression value*
Low ( )High ( )

Age (means ± SD, years)56.03 ± 12.8656.26 ± 11.140.436
Gender0.128
 Male35 (62.3%)20 (66.1%)
 Female21 (37.7%)10 (33.9%)
Tumor location0.526
 Proximal3 (5%)1 (3%)
 Body24 (42.6%)12 (41%)
 Distal28 (50.4%)17 (56%)
Histologic type<0.001
 Differentiated19 (34.3%)7 (22.5%)
 Undifferentiated37 (65.7%)23 (77.5%)
T stage<0.001
 T137 (66.7%)15 (49.3%)
 T212 (21.4%)7 (23.6%)
 T37 (11.9%)5 (18.1%)
 T40 (0%)3 (9%)
Lymph node metastasis<0.001
 Present17 (30.5%)26 (85.3%)
 Absent39 (69.5%)4 (14.7%)
Liver metastasis0.266
 Present27 (47.8%)15 (50.3%)
 Absent29 (52.2%)15 (49.7%)
Peritoneal metastasis0.137
 Present32 (57.8%)18 (61.2%)
 Absent24 (42.2%)12 (38.8%)
pTNM stage<0.05
 I29 (52.6%)12 (41.1%)
 II16 (27.8%)7 (21.8%)
 III6 (11.3%)6 (19.3%)
 IV5 (8.3%)5 (17.8%)

value was tested in univariate analysis.